HIV Drug Maraviroc May Slow Prostate Cancer

“A drug used to treat HIV infection can slow the spread of prostate cancer, research has shown.

“Early studies have shown the antiretroviral drug maraviroc can dramatically curb the spread of prostate cancer, that claims around 10,000 lives in the UK each year. Prostate cancer tumours most commonly travels to the bones, but treatment with maraviroc reduced the spread to the bones, brain and other organs by 60 per cent in mice.

“Dr Richard Pestell, from Thomas Jefferson University in Philadelphia, said: ‘Because this work shows we can dramatically reduce metastasis in pre-clinical models, and because the drug is already… approved for HIV treatment, we may be able to test soon whether this drug can block metastasis in patients with prostate cancer.’ ”


Human immunodeficiency virus status has no effect on survival in patients with non-small cell lung cancer

Human immunodeficiency virus infection alone should not affect the management of patients with non-small cell lung cancer, this study suggests.


Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.


Combined BRAF and MEK Inhibition Improves Outcome in Metastatic Melanoma

The combination of dabrafenib and trametinib is safe and effective in BRAF-mutant melanoma.


PLOS ONE: The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world.


How necessary is a sentinel node biopsy for melanoma?

A new report weighs the pros and cons of a sentinel node biopsy for melanoma patients.


National Cancer Institute Report shows cancer death rates dropping for most but not all cancers

The Annual Report on the status of cancer shows a decline in cancer deaths from major cancers including lung, colorectal, prostate, and breast, but some cancer deaths continue to increase specifically for men with melanoma as well as for those with liver, uterine, and pancreatic cancers.


Sorafenib does not improve survival in metastatic melanoma Phase III Trial Shows

Sorafenib plus chemotherapy did not improve the overall survival of metastatic melanoma patients not previously treated with chemotherapy. The trial results are published in the Journal of Clinical Oncology.


Wound Complications after Inguinal Lymph Node Lower Than Previously Reported Than in Previous Single Institution Trials

Of 281 cutaneous melanoma patients undergoing inguinal lymph node (ILND) dissection, 14% had wound complications, a rate much lower than those reported in previous single institution studies. In a multivariable model, obesity, and diabetes were significantly associated with wound complications. There was no difference in the rate of reoperation in patients with and without wound complications. The study concludes that the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) appears to underreport the actual incidence of wound complications after ILND.